Avitaminosis (Hypovitaminosis) – Pipeline Review, H2 2012

Avitaminosis (Hypovitaminosis) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Avitaminosis (Hypovitaminosis) – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Avitaminosis (Hypovitaminosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Avitaminosis (Hypovitaminosis). Avitaminosis (Hypovitaminosis) – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Avitaminosis (Hypovitaminosis).
- A review of the Avitaminosis (Hypovitaminosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Avitaminosis (Hypovitaminosis) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Avitaminosis (Hypovitaminosis).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Avitaminosis (Hypovitaminosis) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Avitaminosis (Hypovitaminosis) – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Avitaminosis (Hypovitaminosis) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Avitaminosis (Hypovitaminosis) 7
Avitaminosis (Hypovitaminosis) Therapeutics under Development by Companies 9
Avitaminosis (Hypovitaminosis) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Avitaminosis (Hypovitaminosis) Therapeutics - Products under Development by Companies 14
Avitaminosis (Hypovitaminosis) Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Avitaminosis (Hypovitaminosis) Therapeutics Development 16
Kyowa Hakko Kirin Co., Ltd. 16
Zeria Pharmaceutical Co Ltd 17
Emisphere Technologies, Inc. 18
Cytochroma Inc. 19
Avitaminosis (Hypovitaminosis) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
sodium phosphate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CTAP-101 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
KRN-23 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
cholecalciferol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Avitaminosis (Hypovitaminosis) Therapeutics - Drug Profile Updates 29
Avitaminosis (Hypovitaminosis) Therapeutics - Dormant Products 32
Avitaminosis (Hypovitaminosis) - Product Development Milestones 33
Featured News & Press Releases 33
Sep 20, 2012: Cytochroma Initiates Phase III Study Of CTAP101 Capsules In Chronic Kidney Disease Patients 33
Nov 02, 2009: Interim Study Data Demonstrate Eligen B12 Oral Formulation Achieves Comparable Results to B12 Injection 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Number of Products Under Development for Avitaminosis (Hypovitaminosis), H2 2012 7
Products under Development for Avitaminosis (Hypovitaminosis) - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Kyowa Hakko Kirin Co., Ltd., H2 2012 16
Zeria Pharmaceutical Co Ltd, H2 2012 17
Emisphere Technologies, Inc., H2 2012 18
Cytochroma Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Avitaminosis (Hypovitaminosis) Therapeutics - Drug Profile Updates 29
Avitaminosis (Hypovitaminosis) Therapeutics - Dormant Products 32

List of Figures
Number of Products under Development for Avitaminosis (Hypovitaminosis), H2 2012 7
Products under Development for Avitaminosis (Hypovitaminosis) - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

• How to Treat Arthritis Effectively ?
  The word arthritis stands for inflammation of joints. It is an umbrella term for over 100 diseases that cause pain, discomfort, disability and several other symptoms amongst individuals. Osteoarthritis is one of the most common types of arthritis, which affects elderly. Several other forms of this disease may affect individuals at a very young age [...]
• Benefits of Set top Boxes Amidst the Wave of Digitization
  A set top unit or box is a useful device that provides content through television sets. Set top box is a term that refers to a device, which is used for broadcasting the content. It is different from the devices that help simple recording of media, such as DVDs. Cable operators and satellite companies provide [...]
• What are the Treatments for Alzheimer’s Disease ?
  Alzheimer’s disease is one of the most common types of dementia. Dementia is the condition defined by significant loss of global cognitive ability in a healthy person. This loss is beyond the normal aging process and it only worsens with the age. Alzheimer’s disease is a serious mental health condition and a progressive brain disease [...]
• Book Publishing Process- A Brief Overview
  Publishing is the process of making certain information available for the public. Many a times, authors have their own publication house or they prefer publishing their books on their own. However, those who are not aware of the media that delivers their content find the book publishing process daunting. Contrary to this belief, book-publishing process [...]
• Understand the Basics before Entering the World of IPTV
  IPTV or internet protocol television is an innovative technology, which has changed the appearance of the television programming across the globe. Internet protocol television provides television programming through broadband connection, which works according to the internet protocols. Television viewers who want to enjoy this viewing experience need to subscribe to the IPTV service and buy [...]

• Italy Healthcare Industry Regulatory and Reimbursement Landscape

The Italian Pharmaceutical Market has Declined in Value Terms Due to the Introduction of Price Cuts and Increasing Focus on the Usage of Generic Drugs in Order to Rein in Ballooning Healthcare Expenditure   The pharmaceutical market (at the consumer …

• Men’s Health & Midlife Women Consumer Market Research Reports

RnRMarketResearch.com offers new market research reports on masculinity Vs health and midlife women embracing power and avoiding invisibility in global consumer markets.   “Masculinity Vs Health: Challenges and Opportunities” and “Midlife Women: Embracing Power and Avoiding Invisibility in Global Consumer …

• France Healthcare Market Regulatory and Reimbursement Landscape

France has a Mature Healthcare Market as it Offers Universal Public Access to Healthcare Facilities and Insurance. The Increasing Disease Burden and the Launch of New Products will Drive the Growth of the Pharmaceutical Market; however, Increasing Focus on Generics …

• Lebanon Cards and Payments Industry Worth 2.4 Million Cards By 2017

Between 2008 and 2012, Lebanon’s cards industry recorded a CAGR of 4.89% in terms of volume and the total number of cards increased from 1.6 million to 2.0 million. The industry has been forecasted to grow at a CAGR of …

• Egypt Cards and Payments Industry Worth 21.3 Million Cards By 2017

Egypt’s card industry witnessed strong growth between 2008 and 2012 recording an impressive CAGR of 14.07% rising from 9.1 million cards to 15.4 million. The industry is forecast to grow at a CAGR of 6.48% between 2013 and 2017, from …

Argentina Pharmaceuticals and Healthcare Report Q3 2013

"...... welldeveloped local manufacturing force and its strategic location mean Argentina remains an appealing prospect.. Headline Expenditure Projections: Pharmaceuticals: ARS39.4bn (US$8.7bn) in 2012 to ARS49.4bn (US$8.9bn) in 2013; +25.3% in local curren......"

Hong Kong Pharmaceuticals and Healthcare Report Q3 2013

"......increasing openness of the Chinese market, which decreases the necessity for firms to set up bases in Hong Kong. Headline Expenditure Projections ? Pharmaceuticals: HKD10.31bn (US$1.33bn) in 2012 to HKD10.77bn (US$1.39bn) in 2013; +4.5% in local curr......"

New Zealand Pharmaceuticals and Healthcare Report Q3 2013

"......n the country. Headline Expenditure Forecasts ? Pharmaceuticals: NZD1.36bn (US$1.10bn) in 2012 to NZD1.37bn (US$1.06bn) in 2013; +0.5% in local currency and -3.8% in US dollar terms. ? Healthcare: NZD21.22bn (US$17.19bn) in 2012 to NZD21.96bn (US$17......."

Taiwan Pharmaceuticals and Healthcare Report Q3 2013

"......e, the Bureau of National Health Insurance (BNHI) in Taiwan is cracking down on prescription drugs waste by tightening its oversight of prescription drug distribution. Therefore, we envisage that main drivers of the Taiwanese pharmaceutical market de......"

Zambia Pharmaceuticals and Healthcare Report Q3 2013

"...... rarely has access to specialist services. There are also other differences in rural/urban healthcare provision, such as those relating to the drug supply chain, drug quality concerns and a lack of modern healthcare facilities in much of the country......."